Titre : Vaccins antiviraux

Vaccins antiviraux : Questions médicales fréquentes

Termes MeSH sélectionnés :

Seroconversion
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Vaccins antiviraux : Questions médicales les plus fréquentes", "headline": "Vaccins antiviraux : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Vaccins antiviraux : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-24", "dateModified": "2025-02-18", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Vaccins antiviraux" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Vaccins", "url": "https://questionsmedicales.fr/mesh/D014612", "about": { "@type": "MedicalCondition", "name": "Vaccins", "code": { "@type": "MedicalCode", "code": "D014612", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Vaccins anti-adénovirus", "alternateName": "Adenovirus Vaccines", "url": "https://questionsmedicales.fr/mesh/D062705", "about": { "@type": "MedicalCondition", "name": "Vaccins anti-adénovirus", "code": { "@type": "MedicalCode", "code": "D062705", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.024" } } }, { "@type": "MedicalWebPage", "name": "Vaccins contre le SIDA", "alternateName": "AIDS Vaccines", "url": "https://questionsmedicales.fr/mesh/D016915", "about": { "@type": "MedicalCondition", "name": "Vaccins contre le SIDA", "code": { "@type": "MedicalCode", "code": "D016915", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.050" } } }, { "@type": "MedicalWebPage", "name": "Vaccins contre la COVID-19", "alternateName": "COVID-19 Vaccines", "url": "https://questionsmedicales.fr/mesh/D000086663", "about": { "@type": "MedicalCondition", "name": "Vaccins contre la COVID-19", "code": { "@type": "MedicalCode", "code": "D000086663", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.085" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Vaccin ChAdOx1 nCoV-19", "alternateName": "ChAdOx1 nCoV-19", "url": "https://questionsmedicales.fr/mesh/D000090985", "about": { "@type": "MedicalCondition", "name": "Vaccin ChAdOx1 nCoV-19", "code": { "@type": "MedicalCode", "code": "D000090985", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.085.063" } } }, { "@type": "MedicalWebPage", "name": "Ad26COVS1", "alternateName": "Ad26COVS1", "url": "https://questionsmedicales.fr/mesh/D000090984", "about": { "@type": "MedicalCondition", "name": "Ad26COVS1", "code": { "@type": "MedicalCode", "code": "D000090984", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.085.125" } } } ] }, { "@type": "MedicalWebPage", "name": "Vaccins contre le cytomégalovirus", "alternateName": "Cytomegalovirus Vaccines", "url": "https://questionsmedicales.fr/mesh/D022482", "about": { "@type": "MedicalCondition", "name": "Vaccins contre le cytomégalovirus", "code": { "@type": "MedicalCode", "code": "D022482", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.120" } } }, { "@type": "MedicalWebPage", "name": "Vaccins contre la dengue", "alternateName": "Dengue Vaccines", "url": "https://questionsmedicales.fr/mesh/D053059", "about": { "@type": "MedicalCondition", "name": "Vaccins contre la dengue", "code": { "@type": "MedicalCode", "code": "D053059", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.162" } } }, { "@type": "MedicalWebPage", "name": "Vaccins contre la maladie à virus Ebola", "alternateName": "Ebola Vaccines", "url": "https://questionsmedicales.fr/mesh/D046129", "about": { "@type": "MedicalCondition", "name": "Vaccins contre la maladie à virus Ebola", "code": { "@type": "MedicalCode", "code": "D046129", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.205" } } }, { "@type": "MedicalWebPage", "name": "Vaccins contre les herpèsvirus", "alternateName": "Herpesvirus Vaccines", "url": "https://questionsmedicales.fr/mesh/D022283", "about": { "@type": "MedicalCondition", "name": "Vaccins contre les herpèsvirus", "code": { "@type": "MedicalCode", "code": "D022283", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.290" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Vaccin contre la varicelle", "alternateName": "Chickenpox Vaccine", "url": "https://questionsmedicales.fr/mesh/D019433", "about": { "@type": "MedicalCondition", "name": "Vaccin contre la varicelle", "code": { "@type": "MedicalCode", "code": "D019433", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.290.130" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Vaccin contre le zona", "alternateName": "Herpes Zoster Vaccine", "url": "https://questionsmedicales.fr/mesh/D053061", "about": { "@type": "MedicalCondition", "name": "Vaccin contre le zona", "code": { "@type": "MedicalCode", "code": "D053061", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.290.130.400" } } } ] }, { "@type": "MedicalWebPage", "name": "Vaccin contre le zona", "alternateName": "Herpes Zoster Vaccine", "url": "https://questionsmedicales.fr/mesh/D053061", "about": { "@type": "MedicalCondition", "name": "Vaccin contre le zona", "code": { "@type": "MedicalCode", "code": "D053061", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.290.130.400" } } }, { "@type": "MedicalWebPage", "name": "Vaccins contre les virus herpès simplex", "alternateName": "Herpes Simplex Virus Vaccines", "url": "https://questionsmedicales.fr/mesh/D022301", "about": { "@type": "MedicalCondition", "name": "Vaccins contre les virus herpès simplex", "code": { "@type": "MedicalCode", "code": "D022301", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.290.400" } } }, { "@type": "MedicalWebPage", "name": "Vaccins contre la maladie de Marek", "alternateName": "Marek Disease Vaccines", "url": "https://questionsmedicales.fr/mesh/D022501", "about": { "@type": "MedicalCondition", "name": "Vaccins contre la maladie de Marek", "code": { "@type": "MedicalCode", "code": "D022501", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.290.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Vaccins antigrippaux", "alternateName": "Influenza Vaccines", "url": "https://questionsmedicales.fr/mesh/D007252", "about": { "@type": "MedicalCondition", "name": "Vaccins antigrippaux", "code": { "@type": "MedicalCode", "code": "D007252", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.302" } } }, { "@type": "MedicalWebPage", "name": "Vaccins contre l'encéphalite japonaise", "alternateName": "Japanese Encephalitis Vaccines", "url": "https://questionsmedicales.fr/mesh/D022321", "about": { "@type": "MedicalCondition", "name": "Vaccins contre l'encéphalite japonaise", "code": { "@type": "MedicalCode", "code": "D022321", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.320" } } }, { "@type": "MedicalWebPage", "name": "Vaccin contre la rougeole", "alternateName": "Measles Vaccine", "url": "https://questionsmedicales.fr/mesh/D008458", "about": { "@type": "MedicalCondition", "name": "Vaccin contre la rougeole", "code": { "@type": "MedicalCode", "code": "D008458", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.404" } } }, { "@type": "MedicalWebPage", "name": "Vaccin antiourlien", "alternateName": "Mumps Vaccine", "url": "https://questionsmedicales.fr/mesh/D009108", "about": { "@type": "MedicalCondition", "name": "Vaccin antiourlien", "code": { "@type": "MedicalCode", "code": "D009108", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.488" } } }, { "@type": "MedicalWebPage", "name": "Vaccins contre les papillomavirus", "alternateName": "Papillomavirus Vaccines", "url": "https://questionsmedicales.fr/mesh/D053918", "about": { "@type": "MedicalCondition", "name": "Vaccins contre les papillomavirus", "code": { "@type": "MedicalCode", "code": "D053918", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.498" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18", "alternateName": "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18", "url": "https://questionsmedicales.fr/mesh/D000068857", "about": { "@type": "MedicalCondition", "name": "Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18", "code": { "@type": "MedicalCode", "code": "D000068857", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.498.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Vaccins contre les virus para-influenza", "alternateName": "Parainfluenza Vaccines", "url": "https://questionsmedicales.fr/mesh/D022241", "about": { "@type": "MedicalCondition", "name": "Vaccins contre les virus para-influenza", "code": { "@type": "MedicalCode", "code": "D022241", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.500" } } }, { "@type": "MedicalWebPage", "name": "Vaccins antipoliomyélitiques", "alternateName": "Poliovirus Vaccines", "url": "https://questionsmedicales.fr/mesh/D023321", "about": { "@type": "MedicalCondition", "name": "Vaccins antipoliomyélitiques", "code": { "@type": "MedicalCode", "code": "D023321", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.623" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Vaccin antipoliomyélitique inactivé", "alternateName": "Poliovirus Vaccine, Inactivated", "url": "https://questionsmedicales.fr/mesh/D011054", "about": { "@type": "MedicalCondition", "name": "Vaccin antipoliomyélitique inactivé", "code": { "@type": "MedicalCode", "code": "D011054", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.623.500" } } }, { "@type": "MedicalWebPage", "name": "Vaccin antipoliomyélitique oral", "alternateName": "Poliovirus Vaccine, Oral", "url": "https://questionsmedicales.fr/mesh/D011055", "about": { "@type": "MedicalCondition", "name": "Vaccin antipoliomyélitique oral", "code": { "@type": "MedicalCode", "code": "D011055", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.623.750" } } } ] }, { "@type": "MedicalWebPage", "name": "Vaccins contre la maladie d'Aujeszky", "alternateName": "Pseudorabies Vaccines", "url": "https://questionsmedicales.fr/mesh/D022421", "about": { "@type": "MedicalCondition", "name": "Vaccins contre la maladie d'Aujeszky", "code": { "@type": "MedicalCode", "code": "D022421", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.632" } } }, { "@type": "MedicalWebPage", "name": "Vaccins antirabiques", "alternateName": "Rabies Vaccines", "url": "https://questionsmedicales.fr/mesh/D011819", "about": { "@type": "MedicalCondition", "name": "Vaccins antirabiques", "code": { "@type": "MedicalCode", "code": "D011819", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.700" } } }, { "@type": "MedicalWebPage", "name": "Vaccins contre les virus respiratoires syncytiaux", "alternateName": "Respiratory Syncytial Virus Vaccines", "url": "https://questionsmedicales.fr/mesh/D022261", "about": { "@type": "MedicalCondition", "name": "Vaccins contre les virus respiratoires syncytiaux", "code": { "@type": "MedicalCode", "code": "D022261", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.730" } } }, { "@type": "MedicalWebPage", "name": "Vaccins anti-rotavirus", "alternateName": "Rotavirus Vaccines", "url": "https://questionsmedicales.fr/mesh/D022243", "about": { "@type": "MedicalCondition", "name": "Vaccins anti-rotavirus", "code": { "@type": "MedicalCode", "code": "D022243", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.760" } } }, { "@type": "MedicalWebPage", "name": "Vaccin antirubéoleux", "alternateName": "Rubella Vaccine", "url": "https://questionsmedicales.fr/mesh/D012411", "about": { "@type": "MedicalCondition", "name": "Vaccin antirubéoleux", "code": { "@type": "MedicalCode", "code": "D012411", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.779" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Vaccin contre la rougeole, les oreillons et la rubéole", "alternateName": "Measles-Mumps-Rubella Vaccine", "url": "https://questionsmedicales.fr/mesh/D022542", "about": { "@type": "MedicalCondition", "name": "Vaccin contre la rougeole, les oreillons et la rubéole", "code": { "@type": "MedicalCode", "code": "D022542", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.779.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Vaccins contre le SIDA simien", "alternateName": "SAIDS Vaccines", "url": "https://questionsmedicales.fr/mesh/D018449", "about": { "@type": "MedicalCondition", "name": "Vaccins contre le SIDA simien", "code": { "@type": "MedicalCode", "code": "D018449", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.790" } } }, { "@type": "MedicalWebPage", "name": "Vaccin antivariolique", "alternateName": "Smallpox Vaccine", "url": "https://questionsmedicales.fr/mesh/D012900", "about": { "@type": "MedicalCondition", "name": "Vaccin antivariolique", "code": { "@type": "MedicalCode", "code": "D012900", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.859" } } }, { "@type": "MedicalWebPage", "name": "Vaccins contre les hépatites virales", "alternateName": "Viral Hepatitis Vaccines", "url": "https://questionsmedicales.fr/mesh/D014761", "about": { "@type": "MedicalCondition", "name": "Vaccins contre les hépatites virales", "code": { "@type": "MedicalCode", "code": "D014761", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.955" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Vaccins anti-hépatite A", "alternateName": "Hepatitis A Vaccines", "url": "https://questionsmedicales.fr/mesh/D022362", "about": { "@type": "MedicalCondition", "name": "Vaccins anti-hépatite A", "code": { "@type": "MedicalCode", "code": "D022362", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.955.395" } } }, { "@type": "MedicalWebPage", "name": "Vaccins anti-hépatite B", "alternateName": "Hepatitis B Vaccines", "url": "https://questionsmedicales.fr/mesh/D017325", "about": { "@type": "MedicalCondition", "name": "Vaccins anti-hépatite B", "code": { "@type": "MedicalCode", "code": "D017325", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.955.400" } } } ] }, { "@type": "MedicalWebPage", "name": "Vaccins contre le virus du Nil occidental", "alternateName": "West Nile Virus Vaccines", "url": "https://questionsmedicales.fr/mesh/D053060", "about": { "@type": "MedicalCondition", "name": "Vaccins contre le virus du Nil occidental", "code": { "@type": "MedicalCode", "code": "D053060", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.962" } } }, { "@type": "MedicalWebPage", "name": "Vaccin antiamaril", "alternateName": "Yellow Fever Vaccine", "url": "https://questionsmedicales.fr/mesh/D022341", "about": { "@type": "MedicalCondition", "name": "Vaccin antiamaril", "code": { "@type": "MedicalCode", "code": "D022341", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D20.215.894.899.970" } } } ], "about": { "@type": "MedicalCondition", "name": "Vaccins antiviraux", "alternateName": "Viral Vaccines", "code": { "@type": "MedicalCode", "code": "D014765", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Yukai Huang", "url": "https://questionsmedicales.fr/author/Yukai%20Huang", "affiliation": { "@type": "Organization", "name": "Department of Microbiology, School of Basic Medicine, Zunyi Medical University, Zunyi, Guizhou, China." } }, { "@type": "Person", "name": "Xiao Guo", "url": "https://questionsmedicales.fr/author/Xiao%20Guo", "affiliation": { "@type": "Organization", "name": "Department of Microbiology, School of Basic Medicine, Zunyi Medical University, Zunyi, Guizhou, China." } }, { "@type": "Person", "name": "Yuancheng Zhou", "url": "https://questionsmedicales.fr/author/Yuancheng%20Zhou", "affiliation": { "@type": "Organization", "name": "Livestock and Poultry Biological Products Key Laboratory of Sichuan Province, Sichuan Animal Science Academy, Chengdu, China." } }, { "@type": "Person", "name": "Dongying Liu", "url": "https://questionsmedicales.fr/author/Dongying%20Liu", "affiliation": { "@type": "Organization", "name": "Department of Microbiology, School of Basic Medicine, Zunyi Medical University, Zunyi, Guizhou, China." } }, { "@type": "Person", "name": "Jingrui Mao", "url": "https://questionsmedicales.fr/author/Jingrui%20Mao", "affiliation": { "@type": "Organization", "name": "Department of Microbiology, School of Basic Medicine, Zunyi Medical University, Zunyi, Guizhou, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Illicit Fentanyl Use and Hepatitis C Virus Seroconversion Among People Who Inject Drugs in Tijuana and San Diego: Results From a Binational Cohort Study.", "datePublished": "2024-07-30", "url": "https://questionsmedicales.fr/article/39078273", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1093/cid/ciae372" } }, { "@type": "ScholarlyArticle", "name": "A prospective cohort study of SARS-CoV-2 infection-induced seroconversion and disease incidence in German healthcare workers before and during the rollout of COVID-19 vaccines.", "datePublished": "2024-01-30", "url": "https://questionsmedicales.fr/article/38289913", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0294025" } }, { "@type": "ScholarlyArticle", "name": "A BOOSTER DOSE OF SARS-CoV-2 VACCINE IMPROVES SUBOPTIMAL SEROCONVERSION RATES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. RESULTS OF A PROSPECTIVE MULTICENTER STUDY OF GETECCU (VACOVEII STUDY).", "datePublished": "2023-11-23", "url": "https://questionsmedicales.fr/article/38007154", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.gastrohep.2023.11.004" } }, { "@type": "ScholarlyArticle", "name": "No seroconversion in a retrospective study analyzing QuantiFERON TB-gold testing in pediatric psoriasis and hidradenitis suppurativa patients taking biologic therapy at an academic center in New York City.", "datePublished": "2024-02-27", "url": "https://questionsmedicales.fr/article/38413181", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/pde.15577" } }, { "@type": "ScholarlyArticle", "name": "Seroconversion in liver and intestine transplant patients after one, two or three doses of adenoviral vector vaccines against SARS-CoV-2. Single center experience in Argentina.", "datePublished": "2024-09-11", "url": "https://questionsmedicales.fr/article/39265411", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.humimm.2024.111091" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Mélanges complexes", "item": "https://questionsmedicales.fr/mesh/D045424" }, { "@type": "ListItem", "position": 3, "name": "Produits biologiques", "item": "https://questionsmedicales.fr/mesh/D001688" }, { "@type": "ListItem", "position": 4, "name": "Vaccins", "item": "https://questionsmedicales.fr/mesh/D014612" }, { "@type": "ListItem", "position": 5, "name": "Vaccins antiviraux", "item": "https://questionsmedicales.fr/mesh/D014765" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Vaccins antiviraux - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Vaccins antiviraux", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Vaccins antiviraux", "description": "Comment diagnostiquer une infection virale ?\nQuels tests sont utilisés pour les vaccins antiviraux ?\nLes symptômes indiquent-ils un besoin de vaccin ?\nComment évaluer l'efficacité d'un vaccin ?\nLes tests de dépistage sont-ils nécessaires avant vaccination ?", "url": "https://questionsmedicales.fr/mesh/D014765?mesh_terms=Seroconversion&page=16#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Vaccins antiviraux", "description": "Quels symptômes nécessitent un vaccin antiviral ?\nLes effets secondaires des vaccins sont-ils fréquents ?\nComment distinguer une infection d'un effet secondaire ?\nLes symptômes varient-ils selon le type de vaccin ?\nLes symptômes d'une infection virale sont-ils similaires ?", "url": "https://questionsmedicales.fr/mesh/D014765?mesh_terms=Seroconversion&page=16#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Vaccins antiviraux", "description": "Comment les vaccins antiviraux préviennent-ils les infections ?\nÀ quel âge doit-on commencer la vaccination antivirale ?\nLes vaccins antiviraux sont-ils sûrs pour les femmes enceintes ?\nLes vaccins protègent-ils contre toutes les souches virales ?\nQuelle est l'importance de la vaccination de masse ?", "url": "https://questionsmedicales.fr/mesh/D014765?mesh_terms=Seroconversion&page=16#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Vaccins antiviraux", "description": "Les vaccins antiviraux sont-ils des traitements ?\nQuels traitements sont disponibles après infection ?\nLes vaccins peuvent-ils réduire la gravité des symptômes ?\nLes traitements sont-ils nécessaires après vaccination ?\nLes vaccins antiviraux nécessitent-ils des traitements préventifs ?", "url": "https://questionsmedicales.fr/mesh/D014765?mesh_terms=Seroconversion&page=16#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Vaccins antiviraux", "description": "Quelles complications peuvent survenir après vaccination ?\nLes complications sont-elles fréquentes ?\nComment gérer les complications post-vaccinales ?\nLes complications varient-elles selon le vaccin ?\nLes complications peuvent-elles affecter l'immunité ?", "url": "https://questionsmedicales.fr/mesh/D014765?mesh_terms=Seroconversion&page=16#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Vaccins antiviraux", "description": "Quels sont les facteurs de risque pour les infections virales ?\nLes antécédents médicaux influencent-ils la vaccination ?\nLes voyages augmentent-ils le risque d'infection ?\nLes personnes âgées ont-elles plus de risques ?\nLe mode de vie influence-t-il le risque d'infection ?", "url": "https://questionsmedicales.fr/mesh/D014765?mesh_terms=Seroconversion&page=16#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une infection virale ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests virologiques, des analyses sanguines et des symptômes cliniques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour les vaccins antiviraux ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sérologiques et des cultures virales sont souvent utilisés pour évaluer l'immunité." } }, { "@type": "Question", "name": "Les symptômes indiquent-ils un besoin de vaccin ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la fièvre ou la fatigue peuvent indiquer une infection nécessitant un vaccin." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité d'un vaccin ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité est évaluée par des études cliniques et des taux d'infection dans la population vaccinée." } }, { "@type": "Question", "name": "Les tests de dépistage sont-ils nécessaires avant vaccination ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des tests peuvent être recommandés pour certaines populations à risque avant la vaccination." } }, { "@type": "Question", "name": "Quels symptômes nécessitent un vaccin antiviral ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la toux, la fièvre ou des douleurs musculaires peuvent indiquer un besoin." } }, { "@type": "Question", "name": "Les effets secondaires des vaccins sont-ils fréquents ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires comme la douleur au site d'injection sont courants mais généralement légers." } }, { "@type": "Question", "name": "Comment distinguer une infection d'un effet secondaire ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les infections présentent des symptômes persistants, tandis que les effets secondaires sont temporaires." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type de vaccin ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier selon le type de vaccin et la réponse immunitaire individuelle." } }, { "@type": "Question", "name": "Les symptômes d'une infection virale sont-ils similaires ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, de nombreuses infections virales partagent des symptômes comme la fièvre et la fatigue." } }, { "@type": "Question", "name": "Comment les vaccins antiviraux préviennent-ils les infections ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Ils stimulent le système immunitaire à reconnaître et combattre les virus spécifiques." } }, { "@type": "Question", "name": "À quel âge doit-on commencer la vaccination antivirale ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "L'âge de vaccination dépend du vaccin, mais beaucoup commencent dès l'enfance." } }, { "@type": "Question", "name": "Les vaccins antiviraux sont-ils sûrs pour les femmes enceintes ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Certains vaccins sont sûrs pendant la grossesse, mais il est essentiel de consulter un médecin." } }, { "@type": "Question", "name": "Les vaccins protègent-ils contre toutes les souches virales ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Non, les vaccins ciblent des souches spécifiques, et des mises à jour peuvent être nécessaires." } }, { "@type": "Question", "name": "Quelle est l'importance de la vaccination de masse ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "La vaccination de masse aide à atteindre l'immunité collective et à réduire la propagation des virus." } }, { "@type": "Question", "name": "Les vaccins antiviraux sont-ils des traitements ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Non, les vaccins préviennent les infections, tandis que les traitements ciblent les infections existantes." } }, { "@type": "Question", "name": "Quels traitements sont disponibles après infection ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des antiviraux comme l'oseltamivir peuvent être prescrits pour traiter certaines infections virales." } }, { "@type": "Question", "name": "Les vaccins peuvent-ils réduire la gravité des symptômes ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les vaccins peuvent atténuer la gravité des symptômes en cas d'infection post-vaccination." } }, { "@type": "Question", "name": "Les traitements sont-ils nécessaires après vaccination ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Pas nécessairement, mais des traitements peuvent être requis si une infection survient malgré la vaccination." } }, { "@type": "Question", "name": "Les vaccins antiviraux nécessitent-ils des traitements préventifs ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Non, les vaccins sont une mesure préventive, mais des traitements peuvent être nécessaires en cas d'exposition." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir après vaccination ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications rares incluent des réactions allergiques sévères ou des syndromes neurologiques." } }, { "@type": "Question", "name": "Les complications sont-elles fréquentes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Non, la plupart des complications sont rares et les bénéfices de la vaccination l'emportent sur les risques." } }, { "@type": "Question", "name": "Comment gérer les complications post-vaccinales ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Consulter un professionnel de santé pour évaluer et traiter les complications éventuelles." } }, { "@type": "Question", "name": "Les complications varient-elles selon le vaccin ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, chaque vaccin peut avoir des profils de complications différents selon sa composition." } }, { "@type": "Question", "name": "Les complications peuvent-elles affecter l'immunité ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent temporairement affecter la réponse immunitaire, mais cela est rare." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les infections virales ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, les maladies chroniques, et l'immunodépression." } }, { "@type": "Question", "name": "Les antécédents médicaux influencent-ils la vaccination ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de réactions allergiques ou de maladies peuvent influencer le choix du vaccin." } }, { "@type": "Question", "name": "Les voyages augmentent-ils le risque d'infection ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, voyager dans des zones à risque peut augmenter l'exposition à des virus spécifiques." } }, { "@type": "Question", "name": "Les personnes âgées ont-elles plus de risques ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées sont plus susceptibles de développer des complications graves liées aux infections." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il le risque d'infection ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sain, incluant une bonne nutrition et de l'exercice, peut réduire le risque." } } ] } ] }

Sous-catégories

36 au total
└─

Vaccins anti-adénovirus

Adenovirus Vaccines D062705 - D20.215.894.899.024
└─

Vaccins contre le SIDA

AIDS Vaccines D016915 - D20.215.894.899.050
└─

Vaccins contre la COVID-19

COVID-19 Vaccines D000086663 - D20.215.894.899.085
└─

Vaccins contre le cytomégalovirus

Cytomegalovirus Vaccines D022482 - D20.215.894.899.120
└─

Vaccins contre la dengue

Dengue Vaccines D053059 - D20.215.894.899.162
└─

Vaccins contre la maladie à virus Ebola

Ebola Vaccines D046129 - D20.215.894.899.205
└─

Vaccins contre les herpèsvirus

Herpesvirus Vaccines D022283 - D20.215.894.899.290
└─

Vaccins antigrippaux

Influenza Vaccines D007252 - D20.215.894.899.302
└─

Vaccins contre l'encéphalite japonaise

Japanese Encephalitis Vaccines D022321 - D20.215.894.899.320
└─

Vaccin contre la rougeole

Measles Vaccine D008458 - D20.215.894.899.404
└─

Vaccin antiourlien

Mumps Vaccine D009108 - D20.215.894.899.488
└─

Vaccins contre les papillomavirus

Papillomavirus Vaccines D053918 - D20.215.894.899.498
└─

Vaccins contre les virus para-influenza

Parainfluenza Vaccines D022241 - D20.215.894.899.500
└─

Vaccins antipoliomyélitiques

Poliovirus Vaccines D023321 - D20.215.894.899.623
└─

Vaccins contre la maladie d'Aujeszky

Pseudorabies Vaccines D022421 - D20.215.894.899.632
└─

Vaccins antirabiques

Rabies Vaccines D011819 - D20.215.894.899.700
└─

Vaccins contre les virus respiratoires syncytiaux

Respiratory Syncytial Virus Vaccines D022261 - D20.215.894.899.730
└─

Vaccins anti-rotavirus

Rotavirus Vaccines D022243 - D20.215.894.899.760
└─

Vaccin antirubéoleux

Rubella Vaccine D012411 - D20.215.894.899.779
└─

Vaccins contre le SIDA simien

SAIDS Vaccines D018449 - D20.215.894.899.790
└─

Vaccin antivariolique

Smallpox Vaccine D012900 - D20.215.894.899.859
└─

Vaccins contre les hépatites virales

Viral Hepatitis Vaccines D014761 - D20.215.894.899.955
└─

Vaccins contre le virus du Nil occidental

West Nile Virus Vaccines D053060 - D20.215.894.899.962
└─

Vaccin antiamaril

Yellow Fever Vaccine D022341 - D20.215.894.899.970
└─└─

Vaccin ChAdOx1 nCoV-19

ChAdOx1 nCoV-19 D000090985 - D20.215.894.899.085.063
└─└─

Ad26COVS1

Ad26COVS1 D000090984 - D20.215.894.899.085.125
└─└─

Vaccin contre la varicelle

Chickenpox Vaccine D019433 - D20.215.894.899.290.130
└─└─

Vaccins contre les virus herpès simplex

Herpes Simplex Virus Vaccines D022301 - D20.215.894.899.290.400
└─└─

Vaccins contre la maladie de Marek

Marek Disease Vaccines D022501 - D20.215.894.899.290.500
└─└─

Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 D000068857 - D20.215.894.899.498.500
└─└─

Vaccin antipoliomyélitique inactivé

Poliovirus Vaccine, Inactivated D011054 - D20.215.894.899.623.500
└─└─

Vaccin antipoliomyélitique oral

Poliovirus Vaccine, Oral D011055 - D20.215.894.899.623.750
└─└─

Vaccin contre la rougeole, les oreillons et la rubéole

Measles-Mumps-Rubella Vaccine D022542 - D20.215.894.899.779.500
└─└─

Vaccins anti-hépatite A

Hepatitis A Vaccines D022362 - D20.215.894.899.955.395
└─└─

Vaccins anti-hépatite B

Hepatitis B Vaccines D017325 - D20.215.894.899.955.400
└─└─└─

Vaccin contre le zona

Herpes Zoster Vaccine D053061 - D20.215.894.899.290.130.400

Sources (162 au total)

Illicit Fentanyl Use and Hepatitis C Virus Seroconversion Among People Who Inject Drugs in Tijuana and San Diego: Results From a Binational Cohort Study.

Illicitly manufactured fentanyl (IMF) increases overdose mortality, but its role in infectious disease transmission is unknown. We examined whether IMF use predicts hepatitis C virus (HCV) and human i... PWID were recruited during 2020-2022, undergoing semi-annual interviewer-administered surveys and HIV and HCV serological rapid tests through 2024. Cox regression was conducted to examine predictors o... Of 398 PWID at baseline, 67% resided in San Diego, 70% were male, median age was 43 years, 42% reported receptive needle sharing, and 25% reported using IMF. HCV incidence was 14.26 per 100 person-yea... We document a novel association between IMF and HCV seroconversion among PWID in Tijuana-San Diego. Few HIV seroconversions (n = 10) precluded our ability to assess if a similar relationship held for ...

A BOOSTER DOSE OF SARS-CoV-2 VACCINE IMPROVES SUBOPTIMAL SEROCONVERSION RATES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. RESULTS OF A PROSPECTIVE MULTICENTER STUDY OF GETECCU (VACOVEII STUDY).

The response to SARS-CoV-2 vaccination decreases in inflammatory bowel disease (IBD) patients, specially under anti-TNF treatment. However, data on medium-term effectiveness are limited, specially usi... VACOVEII is a Spanish multicenter, prospective study promoted by GETECCU. IBD patients full vaccinated against SARS-CoV-2 and without previous COVID-19 infection, treated or not with immunosuppressant... Between October 2021 and March 2022, 313 patients were included (124 no treatment or mesalazine; 55 immunomodulators; 87 anti-TNF; 19 anti-integrin; and 28 ustekinumab). Most patients received mRNA-va... The full vaccination regimen achieves suboptimal response in IBD patients, specially among those anti-TNF or ustekinumab. The booster dose improves seroconversion rate in all patients, although it rem...

Seroconversion in liver and intestine transplant patients after one, two or three doses of adenoviral vector vaccines against SARS-CoV-2. Single center experience in Argentina.

The capacity of different anti-SARS-CoV-2 vaccines to elicit immune response is not equivalent in the healthy population compared to chronically immunosuppressed patients. Most of the reports availabl... This study aims to assess the seroconversion rate in a cohort of liver and liver- intestinal transplant patients after vaccination with the non-replicative vector-based vaccines after transplantation ... One hundred and three (103) liver and liver-intestinal transplant recipients were enrolled. Patients with previous PCR-confirmed COVID19 were excluded, therefore 77 were finally included for analysis;... Following the three doses, 57.1 % (44/77) of the patients seroconverted, while 33/77 (42.9 %) did not present anti-SARS-CoV-2 antibodies. The seroconversion rate was different for each dose. We found ... Despite having a lower seroconversion rate compared to the general population, viral-vector vaccines benefit SOTR patients increasing the seroconversion rate using at least two doses of vaccine. These...

Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines.

The aim of this study was to assess the immune response after a third dose of SARS-CoV-2 vaccine in patients with rheumatoid arthritis (RA) with undetectable antibody titers after the primary regimen ... Patients with RA with no seroconversion after 2 doses of SARS-CoV-2 vaccine and who received a third dose of either an mRNA or vector-based vaccine were included. Anti-SARS-CoV-2 IgG antibodies, neutr... A total of 21 nonresponder patients were included. At the time of vaccination, 29% were receiving glucocorticoids and 85% biologic disease-modifying antirheumatic drugs (including 6 taking abatacept [... In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower...

T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination.

Messenger RNA (mRNA) vaccines provide robust protection against SARS-CoV-2 in healthy individuals. However, immunity after vaccination of patients with multiple sclerosis (MS) treated with ocrelizumab... In this study, deep immune profiling techniques were employed to investigate the immune response induced by SARS-CoV-2 mRNA vaccines in untreated patients with MS (n=21), OCR-treated patients with MS ... Among OCR-treated patients with MS, 63% did not produce detectable levels of antibodies (non-seroconverted), and those who did have lower spike receptor-binding domain-specific IgG responses compared ... These findings highlight the importance of optimising treatment regimens when scheduling SARS-CoV-2 vaccination for OCR-treated patients with MS to maximise their humoral and cellular immune responses...

Hepatitis B surface antigen reverse seroconversion after hematopoietic stem cell transplantation according to the baseline serological marker levels and vaccination status: a single-center database analysis.

Hepatitis B is a major prognostic factor after hematopoietic stem cell transplantation (HSCT). Currently, no consensus exists regarding the management of various scenarios that can lead to reverse ser... This single-center retrospective study utilized clinical data extracted from the electronic medical records of Seoul St. Mary's Hospital, Korea. Patients who underwent HSCT between January 2013 and De... This study included 1,344 patients, of whom 83.3% tested positive for the hepatitis B surface antibody (HBsAb) during HSCT. HBsAg-RS occurred in 2.2% of HBsAb-negative patients and 3.0% of HBsAb-posit... The sufficient patient population enabled the identification of an association between baseline HBcAb positivity and the development of HBsAg-RS. Further prospective studies are warranted to determine...

A Serum Multi-Parametric Analysis Identifies an Early Innate Immune Signature Associated to Increased Vaccine-Specific Antibody Production and Seroconversion in Simultaneous COVID-19 mRNA and Cell-Based Quadrivalent Influenza Vaccination.

In this pilot study, a multi-parametric analysis comparing immune responses in sera of adult healthy subjects (HS) or people with type 2 diabetes mellitus (T2D) undergoing the single or simultaneous a...